These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38361989)

  • 1. Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
    Paton NI; Stöhr W; Arenas-Pinto A; Clarke A; Williams I; Johnson M; Orkin C; Chen F; Lee V; Winston A; Gompels M; Fox J; Sanders K; Dunn DT;
    EClinicalMedicine; 2024 Mar; 69():102457. PubMed ID: 38361989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
    Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
    Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.
    Paton NI; Stöhr W; Arenas-Pinto A; Fisher M; Williams I; Johnson M; Orkin C; Chen F; Lee V; Winston A; Gompels M; Fox J; Scott K; Dunn DT;
    Lancet HIV; 2015 Oct; 2(10):e417-26. PubMed ID: 26423649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.
    Oddershede L; Walker S; Stöhr W; Dunn DT; Arenas-Pinto A; Paton NI; Sculpher M;
    Pharmacoeconomics; 2016 Aug; 34(8):795-804. PubMed ID: 26966125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.
    Dunn DT; Stöhr W; Arenas-Pinto A; Tostevin A; Mbisa JL; Paton NI;
    J Clin Virol; 2018 Apr; 101():63-65. PubMed ID: 29428459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
    Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
    Thompson JA; Kityo C; Dunn D; Hoppe A; Ndashimye E; Hakim J; Kambugu A; van Oosterhout JJ; Arribas J; Mugyenyi P; Walker AS; Paton NI;
    Clin Infect Dis; 2019 Mar; 68(7):1184-1192. PubMed ID: 30060027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.
    Stöhr W; Dunn DT; Arenas-Pinto A; Orkin C; Clarke A; Williams I; Johnson M; Beeching NJ; Wilkins E; Sanders K; Paton NI;
    AIDS; 2016 Nov; 30(17):2617-2624. PubMed ID: 27456983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
    Daar ES; DeJesus E; Ruane P; Crofoot G; Oguchi G; Creticos C; Rockstroh JK; Molina JM; Koenig E; Liu YP; Custodio J; Andreatta K; Graham H; Cheng A; Martin H; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e347-e356. PubMed ID: 29925490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials.
    Arribas J; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19788. PubMed ID: 25397532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
    Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
    Hakim JG; Thompson J; Kityo C; Hoppe A; Kambugu A; van Oosterhout JJ; Lugemwa A; Siika A; Mwebaze R; Mweemba A; Abongomera G; Thomason MJ; Easterbrook P; Mugyenyi P; Walker AS; Paton NI;
    Lancet Infect Dis; 2018 Jan; 18(1):47-57. PubMed ID: 29108797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.
    Arenas-Pinto A; Stöhr W; Jäger HR; Haddow L; Clarke A; Johnson M; Chen F; Winston A; Godi C; Thust S; Trombin R; Cairns J; Solanky BS; Golay X; Paton NI;
    Clin Infect Dis; 2016 Jul; 63(2):257-64. PubMed ID: 27143662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
    Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
    Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy.
    Kahlert C; Bregenzer A; Gutmann C; Otterbech S; Hoffmann M; Schmid P; Vernazza P
    Infection; 2016 Jun; 44(3):329-35. PubMed ID: 26661659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
    Kityo C; Szubert AJ; Siika A; Heyderman R; Bwakura-Dangarembizi M; Lugemwa A; Mwaringa S; Griffiths A; Nkanya I; Kabahenda S; Wachira S; Musoro G; Rajapakse C; Etyang T; Abach J; Spyer MJ; Wavamunno P; Nyondo-Mipando L; Chidziva E; Nathoo K; Klein N; Hakim J; Gibb DM; Walker AS; Pett SL;
    PLoS Med; 2018 Dec; 15(12):e1002706. PubMed ID: 30513108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.